XML 33 R24.htm IDEA: XBRL DOCUMENT
v3.22.2

Segment and Geographic Information | 9 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Segment and Geographic Information | 14. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in three reportable segments: the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment. As discussed in Note 3, “Discontinued Operations”, our Semiconductor Solutions Group reportable segment has been classified as a discontinued operation. The sale of the semiconductor automation business was completed on February 1, 2022. Historical information has been adjusted to reflect the new reportable segments. The Life Sciences Products segment provides automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and instruments, that help customers manage samples throughout their research discovery and development workflows. The segment’s product offerings include automated cold storage systems, cryogenic storage systems, consumables and instruments and the associated services business for these products. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, as well as sample-based laboratory services to advance scientific research and support drug development. The segment’s service offerings include sample storage, genomic sequencing, gene synthesis, laboratory processing services, laboratory analysis, biospecimen procurement services and other support services which are provided to a wide range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories and research institutes. Our Sample Repository Solutions business is a global leader in sample and material storage and management and provides a full suite of reliable cold and ultra-cold chain solutions. The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the acquisition accounting impact on inventory contracts acquired, restructuring related charges and other special charges, such as impairment losses, as the primary performance metric when evaluating the business. The following is the summary of the financial information for the Company’s reportable segments for the three and nine months ended June 30, 2022 and 2021 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended June 30, | ​ | ​ | Nine Months Ended June 30, | ​
​ | ​ | ​ | 2022 | ​ | 2021 | ​ | 2022 | ​ | 2021 | ​
Revenue: |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | ​
Life Sciences Products | ​ | ​ | $ | 47,369 | ​ | $ | 48,625 | ​ | $ | 150,861 | ​ | $ | 146,520 | ​
Life Sciences Services | ​ | ​ |  | 85,366 | ​ |  | 80,462 | ​ |  | 267,070 | ​ |  | 230,244 | ​
Total revenue | ​ | ​ | $ | 132,735 | ​ | $ | 129,087 | ​ | $ | 417,931 | ​ | $ | 376,764 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss: | ​ | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Products | ​ | ​ | $ | 2,216 | ​ | $ | 5,060 | ​ | $ | 11,895 | ​ | $ | 16,492 | ​
Life Sciences Services | ​ | ​ |  | 2,251 | ​ |  | 5,774 | ​ |  | 14,997 | ​ |  | 18,316 | ​
Reportable segment adjusted operating income | ​ | ​ | ​ | 4,467 | ​ | ​ | 10,834 | ​ | ​ | 26,892 | ​ | ​ | 34,808 | ​
Amortization of completed technology | ​ | ​ | ​ | 1,810 | ​ | ​ | 2,173 | ​ | ​ | 5,424 | ​ | ​ | 6,200 | ​
Amortization of other intangible assets | ​ | ​ | ​ | 5,745 | ​ | ​ | 7,396 | ​ | ​ | 18,064 | ​ | ​ | 21,657 | ​
Restructuring charges | ​ | ​ | ​ | 25 | ​ | ​ | — | ​ | ​ | 319 | ​ | ​ | 53 | ​
Tariff adjustment | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (486) | ​ | ​ | 5,414 | ​
Other unallocated corporate expenses | ​ | ​ | ​ | 1,960 | ​ | ​ | 2,148 | ​ | ​ | 13,677 | ​ | ​ | 11,331 | ​
Total operating loss | ​ | ​ | ​ | (5,073) | ​ | ​ | (883) | ​ | ​ | (10,106) | ​ | ​ | (9,847) | ​
Interest income | ​ | ​ | ​ | 6,822 | ​ | ​ | 409 | ​ | ​ | 9,933 | ​ | ​ | 503 | ​
Interest expense | ​ | ​ | ​ | (2,101) | ​ | ​ | (477) | ​ | ​ | (4,111) | ​ | ​ | (1,485) | ​
Loss on extinguishment of debt | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (632) | ​ | ​ | — | ​
Other income (expenses), net | ​ | ​ | ​ | 630 | ​ | ​ | (1,651) | ​ | ​ | (1,617) | ​ | ​ | (263) | ​
Income (loss) before income taxes | ​ | ​ | $ | 278 | ​ | $ | (2,602) | ​ | $ | (6,533) | ​ | $ | (11,092) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Assets: | ​ | ​ | ​ | Life Sciences Products | ​ | ​ | Life Sciences Services | ​ | ​ | Total | ​ | ​ | ​ | ​
June 30, 2022 | ​ | ​ | $ | 319,632 | ​ | $ | 876,589 | ​ | $ | 1,196,221 | ​ | ​ | ​ | ​
September 30, 2021 | ​ | ​ |  | 278,769 | ​ | ​ | 780,238 | ​ |  | 1,059,007 | ​ | ​ | ​ | ​
​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of June 30, 2022 and September 30, 2021 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | September 30,
​ | ​ | 2022 | ​ | 2021
Segment assets |  | $ | 1,196,221 |  | $ | 1,059,007
Cash and cash equivalents, restricted cash, and marketable securities | ​ |  | 2,507,326 | ​ |  | 244,012
Deferred tax assets | ​ |  | 1,926 | ​ |  | 10,043
Other assets | ​ | ​ | 17,244 | ​ | ​ | 11,237
Assets held for sale | ​ |  | — | ​ |  | 495,213
Total assets | ​ | $ | 3,722,717 | ​ | $ | 1,819,512
​ Revenue from external customers is attributed to geographic areas based on locations to which customer orders are shipped. Net revenue by geographic area for the three and nine months ended June 30, 2022 and 2021 (in thousands) are as follows: ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended June 30, | ​ | ​ | Nine Months Ended June 30, | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2022 | ​ | 2021 | ​ | ​
Geographic Location: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
North America | ​ | $ | 88,557 | ​ | $ | 83,638 | ​ | $ | 285,283 | ​ | $ | 236,939 | ​ | ​
Europe | ​ | ​ | 25,042 | ​ | ​ | 27,009 | ​ | ​ | 75,863 | ​ | ​ | 82,412 | ​ | ​
China | ​ | ​ | 12,906 | ​ | ​ | 11,077 | ​ | ​ | 33,936 | ​ | ​ | 33,869 | ​ | ​
Asia Pacific/ Other | ​ | ​ | 6,230 | ​ | ​ | 7,363 | ​ | ​ | 22,849 | ​ | ​ | 23,544 | ​ | ​
Total | ​ | $ | 132,735 | ​ | $ | 129,087 | ​ | $ | 417,931 | ​ | $ | 376,764 | ​ | ​
​ ​ Revenue for the United States comprises 99% of the revenue for North America for the three and nine months ended June 30, 2022 and 2021.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration